Provenge
Provenge is a treatment for
asymptomatic or minimally symptomatic, metastatic, castrate-resistent
(hormone refractory) prostate cancer. The mets can only be bone or soft
tissue, and the patient can't be on narcotics for cancer-related pain.
The patient must have had no chemo in the previous three months or
steroids in 28 days, and must have an ECOG status of 0-1 (e.g.,
generally feels okay). According to Dendreon and research studies,
Provenge is the only prostate drug to extend survival for this
particular type of prostate cancer beyond two years. It is also the
first FDA-approved immunotherapy vaccine.
Intratumoral Chemo for Pancreatic Cancer
At Cancer Treatment Centers of America in Tulsa, where appropriate, an endoscopic ultrasound (EUS) is used to reach the pancreas and inject chemotherapy directly into the tumor. This procedure is done once a week for four weeks, with a CT scan completed before the first treatment and after the final one to gauge results. Pancreatic intratumoral chemotherapy is an adjuvant treatment, so patients can still receive normal chemotherapy, treatment, etc., while receiving this procedure.
http://www.hopenavigators.com/tipping-the-scales/cutting-edge-technology/provenge-and-intratumoral-chemo-for-pancreatic-cancer
Intratumoral Chemo for Pancreatic Cancer
At Cancer Treatment Centers of America in Tulsa, where appropriate, an endoscopic ultrasound (EUS) is used to reach the pancreas and inject chemotherapy directly into the tumor. This procedure is done once a week for four weeks, with a CT scan completed before the first treatment and after the final one to gauge results. Pancreatic intratumoral chemotherapy is an adjuvant treatment, so patients can still receive normal chemotherapy, treatment, etc., while receiving this procedure.
http://www.hopenavigators.com/tipping-the-scales/cutting-edge-technology/provenge-and-intratumoral-chemo-for-pancreatic-cancer
No comments:
Post a Comment